Compare Heron Therapeutics Inc (HRTX) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares MSCI India ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while iShares MSCI India ETF trades at $48.83. The key difference: iShares MSCI India ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | INDA | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.96 | $55.29 |
52-Week Low | $0.39 | $45.42 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
INDA trades at $48.56, down 0.72% on the day, with neutral technical signals overall. The ETF shows bullish moving averages but neutral oscillators, with key support and resistance clustered around $49. Recent news highlights India's strong 7.8% GDP growth (CNBC, 2026-06-05) and ongoing comparisons with other India-focused ETFs amid foreign investor outflows.
The outlook remains mixed: India's robust economic expansion and strategic sector composition offer growth potential, but risks include geopolitical tensions, AI investment underperformance, and regulatory changes in clean energy. Analyst sentiment is cautiously optimistic, with some seeing value in INDA's discount to S&P 500 valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
